July 20, 2026 Definium Therapeutics Inc. Announces Inducement Grants for New Hires Definium Therapeutics has issued inducement grants to new hires, aiming to attract top talent in the biopharmaceutical sector. This strategic move supports employee retention and aligns with its mission to innovate psychiatric care. The company focuses on developing accessible treatments for mental health disorders.
July 16, 2026 Definium Therapeutics Launches Initiative to Enhance Understanding of Generalized Anxiety Disorder Definium Therapeutics has launched 'Wired for Worry', an initiative aimed at improving awareness and understanding of Generalized Anxiety Disorder (GAD). This program equips healthcare providers with crucial resources and emphasizes the importance of early identification and effective treatment of GAD.
July 14, 2026 Definium Therapeutics Unveils Critical Insights on Generalized Anxiety Disorder Treatment Patterns A new study by Definium Therapeutics reveals high rates of treatment discontinuation and switching among Generalized Anxiety Disorder (GAD) patients, indicating a critical need for innovative therapies. The research emphasizes that many patients do not receive adequate care, with significant gaps and challenges in current treatment options.
July 06, 2026 Definium Therapeutics Inc. Announces Inducement Grants for New Employees Definium Therapeutics Inc. has issued inducement grants for eight new hires, awarding options for 169,740 shares. This initiative aims to attract talent and align employees with the company's long-term goals while adhering to NASDAQ regulations.
June 25, 2026 Definium Therapeutics Closes $805 Million Public Offering: A Major Step Forward in Psychiatric and Neurological Treatments Definium Therapeutics has successfully closed an $805 million public offering, aimed at funding research and development for psychiatric and neurological therapies. With strong underwriting support, this capital will boost their mission to innovate in mental health care, especially with their promising candidate DT120 ODT.
June 24, 2026 Definium Therapeutics Inc. Announces Upsized $700 Million Public Offering Definium Therapeutics, Inc. has launched a $700 million public offering, selling 20.5 million shares to fund R&D for its lead candidate, DT120 ODT. The offering aims to bolster its operations and prepare for commercialization, positioning the company for significant growth in mental health care.
June 22, 2026 Definium Therapeutics Announces Positive Results from Phase 3 Emerge Study for DT120 in Major Depressive Disorder Definium Therapeutics has reported promising results from its Phase 3 Emerge study on DT120, an innovative treatment for Major Depressive Disorder. The trial demonstrated significant improvements in depressive symptoms, with a favorable safety profile, paving the way for potential FDA submission.
June 22, 2026 Definium Therapeutics Inc. Announces $500 Million Public Offering Definium Therapeutics has announced a $500 million public offering to enhance its financial resources for developing treatments for psychiatric and neurological disorders. The proceeds will primarily support R&D and commercialization efforts, particularly for its product candidate DT120 ODT. The offering, managed by leading financial institutions, is poised to significantly impact the company's growth trajectory in the biopharmaceutical landscape.
June 21, 2026 Definium Therapeutics Set to Reveal Phase 3 Emerge Study Results on Major Depressive Disorder Definium Therapeutics will host a webcast on June 22, revealing results from their pivotal Phase 3 Emerge study evaluating DT120 ODT for major depressive disorder. The study assesses the treatment's efficacy and safety, aiming to transform mental health care with innovative therapeutics.
June 15, 2026 Definium Therapeutics Announces Strategic Employee Inducement Grants Definium Therapeutics has issued inducement grants to six newly hired employees to attract top talent and enhance its workforce. The grants, totaling 155,480 shares, reinforce the company's mission to innovate in mental health care through psychedelic therapies.
June 01, 2026 Definium Therapeutics Boosts Workforce with Employee Inducement Grants Definium Therapeutics has issued employee inducement grants to thirteen new hires, offering options to purchase 462,190 shares. This move aims to attract talent as the company develops innovative treatments for psychiatric disorders.
May 21, 2026 Definium Therapeutics to Showcase Innovations at the 2026 Jefferies Global Healthcare Conference Definium Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, showcasing their innovative approach to psychiatric treatments using psychedelics. The company aims to address the mental health crisis by providing evidence-based solutions for patients worldwide.
May 07, 2026 Definium Therapeutics Reports Strong First Quarter 2026 Financial Results Amidst Expanding Clinical Program Definium Therapeutics has announced strong first quarter results for 2026, showcasing significant clinical milestones and a robust financial position. With multiple studies underway, the company is strategically positioned to advance its innovative therapies for psychiatric disorders, including PTSD.
April 30, 2026 Definium Therapeutics Set to Reveal Q1 2026 Financial Results Definium Therapeutics will host a webcast on May 7, 2026, to discuss Q1 financial results and recent developments in psychiatric treatments. The event highlights the company's commitment to revolutionizing mental health care through evidence-based solutions.
April 22, 2026 Definium Therapeutics Inc. Showcases Clinical Advancements and Strategy at Investor and Analyst Day Definium Therapeutics showcased pivotal updates on its DT120 ODT clinical program at the Investor and Analyst Day. The company is focused on treating major psychiatric conditions and is poised for significant growth with upcoming trial data expected in 2026.
April 20, 2026 Definium Therapeutics Inc. Announces Employee Inducement Grants Definium Therapeutics has announced inducement grants to five new non-executive employees, aiming to attract top talent in the biopharmaceutical sector. The grants, totaling 70,860 share options, are designed to align employee incentives with company performance and foster long-term loyalty. This initiative supports Definium's mission to innovate in mental health treatment.
April 18, 2026 Definium Therapeutics Applauds Executive Order to Enhance Mental Health Innovation Definium Therapeutics endorses a recent Executive Order that accelerates mental health research, particularly in psychedelic treatments. The company is advancing its DT120 therapy for anxiety and depression, aiming to revolutionize mental health care with innovative solutions.
April 09, 2026 Definium Therapeutics Engages Investors with Upcoming Conference Participation Definium Therapeutics is set to participate in several key investor conferences in April and May 2026, showcasing its commitment to transparency and innovation in psychiatric care. Key events include a fireside chat and an Investor & Analyst Day, providing opportunities for stakeholders to engage with the company's management.
March 31, 2026 Rising Prevalence of Generalized Anxiety Disorder: Insights from Definium Therapeutics' Latest Study A recent study by Definium Therapeutics shows that the prevalence of Generalized Anxiety Disorder (GAD) in the U.S. has risen from 5.4% to 6.6% between 2020 and 2023. The findings emphasize the need for improved treatment options and integrated care strategies, particularly for women and those with comorbid conditions like Major Depressive Disorder.
March 30, 2026 Definium Therapeutics Expands Workforce with Inducement Grants Definium Therapeutics has issued inducement grants to three new hires, offering options to purchase shares as part of a strategy to strengthen its workforce. This move aligns with the company's mission to innovate in psychiatric and neurological care while complying with NASDAQ regulations.
March 26, 2026 Definium Therapeutics Gears Up for Investor and Analyst Day in New York Definium Therapeutics will host its Investor and Analyst Day in New York on April 22, 2026, focusing on its lead program DT120 ODT for treating anxiety and depression. The event will feature presentations from industry experts and address market opportunities and data readouts that could impact investor sentiment.
February 26, 2026 Mind Medicine Inc. 2025 Annual Report: A Year of Growth and Innovation Mind Medicine Inc.'s 2025 report reveals significant progress in clinical trials for DT120 and DT402, alongside financial challenges with a net loss of $183.8 million. The company is rebranding to Definium Therapeutics, Inc. as it aims to revolutionize mental health treatments.
December 18, 2025 MindMed Gears Up for Key Presentation at J.P. Morgan Healthcare Conference MindMed will participate in the J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its innovations in psychiatry. With three critical Phase 3 readouts approaching, the company aims to engage with investors and highlight its commitment to transforming mental health treatments.
December 15, 2025 Mind Medicine Inc. Announces Employee Inducement Grant Mind Medicine (MindMed) Inc. has announced inducement grants for two new employees, offering options to purchase 31,500 shares. This strategic move emphasizes MindMed's commitment to attracting talent while promoting long-term employee engagement.
December 01, 2025 Mind Medicine Inc. Announces Employee Inducement Grants Mind Medicine Inc. has announced inducement grants for four new non-executive employees, totaling 182,100 common shares. This strategic move aims to attract and retain top talent while aligning their interests with the company's long-term goals in the biopharmaceutical sector.
November 06, 2025 Mind Medicine Inc. Reports Strong Q3 2025 Results and Significant Business Developments Mind Medicine Inc. has reported strong Q3 2025 results, highlighted by a $258.9 million financing round and significant progress in clinical trials. The company is gearing up for a transformative 2026 with multiple Phase 3 trials underway for treatments targeting anxiety, depression, and autism spectrum disorders.
November 06, 2025 Mind Medicine Inc. Reports Q3 2025 Financial Results: A Deep Dive into Growth and Challenges Mind Medicine Inc. reports significant financial challenges in Q3 2025, with operating expenses increasing dramatically. Despite a net loss of $67.3 million, the company remains committed to advancing its promising pipelines for mental health treatments.
November 05, 2025 Mind Medicine Inc. Engages Investors with Upcoming Conference Participation Mind Medicine Inc. is set to participate in several upcoming investor conferences, including the Stifel and Jefferies Healthcare Conferences. The company will highlight its innovative product pipeline and commitment to advancing brain health treatments. Audio webcasts of the presentations will be available for investors to access afterward.
November 03, 2025 Mind Medicine Inc. Announces New Employee Inducement Grant Mind Medicine Inc. has issued inducement grants for three new employees, providing options for 90,750 shares to attract top talent. This strategy aims to enhance employee retention as MindMed advances its commitment to innovative brain health therapies.
November 03, 2025 Mind Medicine Inc. Closes $259 Million Public Offering: A Step Forward in Brain Health Treatment Mind Medicine Inc. has successfully raised $259 million through a public offering, aiming to enhance its research and development of brain health treatments. The funding will support its innovative initiatives and potential future acquisitions, positioning the company as a leader in the field of psychedelic-assisted therapies.
October 30, 2025 Mind Medicine Inc. Set to Announce Q3 2025 Financial Results Mind Medicine Inc. is set to announce its Q3 financial results on November 6, 2025, during a live webcast. Investors are eager for updates on clinical trials and partnerships as the company aims to lead in brain health therapies.
October 30, 2025 Mind Medicine Inc. Secures $225 Million in Public Offering Mind Medicine Inc. has announced a public offering of 18.375 million shares, raising approximately $225 million. The funds will be used for R&D and potential acquisitions in brain health treatments.
October 29, 2025 Mind Medicine Inc. Announces Proposed Public Offering: A Strategic Move for Growth Mind Medicine Inc. has announced a proposed public offering aimed at raising capital to support its research and development of treatments for brain health disorders. The offering is subject to market conditions and managed by notable financial institutions.
October 14, 2025 Mind Medicine Inc. Announces Employee Inducement Grant: A Strategic Move for Growth Mind Medicine (MindMed) Inc. has issued an employee inducement grant to attract talent as it advances its clinical pipeline. The grant includes a stock option for 28,000 shares with a four-year vesting period, aligning employee performance with corporate goals.
September 22, 2025 Mind Medicine Inc. Announces Inducement Grants for New Employees Mind Medicine Inc. recently issued inducement grants to attract new talent, offering options for 182,800 shares to three non-executive employees. This initiative supports the company's mission in brain health treatment while ensuring compliance with NASDAQ regulations.
May 13, 2025 Mind Medicine Inc. Set to Showcase Innovations at 2025 RBC Capital Markets Global Healthcare Conference Mind Medicine Inc. will participate in the 2025 RBC Capital Markets Global Healthcare Conference, presenting its innovative product pipeline for brain health disorders. The event will feature a fireside chat and one-on-one meetings, accessible via an audio webcast.
May 08, 2025 Mind Medicine Inc. Reports Q1 2025 Financial Results: A Promising Outlook Amidst Losses Mind Medicine Inc. has reported a narrowed net loss for Q1 2025, showcasing advancements in its clinical programs, particularly MM120 for anxiety disorders. With strong liquidity and strategic financial moves, the company is well-positioned for future growth in mental health treatments.
May 08, 2025 Mind Medicine Inc. Reports First Quarter 2025 Financial Results and Business Updates Mind Medicine (MindMed) Inc. released its Q1 2025 financial results, showcasing robust progress in Phase 3 clinical trials for generalized anxiety and major depressive disorders. The company has appointed a new Chief Commercial Officer and secured an amended loan agreement to bolster financial stability.
April 24, 2025 Mind Medicine Inc. to Announce First Quarter 2025 Financial Results Mind Medicine (MindMed) Inc. will announce its financial results for Q1 2025 on May 8, 2025, during a live webcast. The event will provide updates on the company's growth and ongoing initiatives, inviting stakeholder engagement.
April 21, 2025 Mind Medicine Inc. Announces New Employee Inducement Grants Mind Medicine Inc. has issued inducement grants for 121,500 shares to attract new non-executive employees. The grants feature a structured vesting schedule to encourage long-term commitment and align interests with shareholders.
April 15, 2025 Mind Medicine Inc. Doses First Patient in Groundbreaking Phase 3 Study for Major Depressive Disorder Mind Medicine Inc. has begun its Phase 3 Emerge study, dosing the first patient with MM120 ODT for Major Depressive Disorder. This study follows promising Phase 2b results and could provide new treatment options for millions suffering from this debilitating condition.
March 06, 2025 Mind Medicine Inc. Reports 2024 Annual Results: A Year of Growth and Challenges Mind Medicine Inc. reports significant advancements in 2024, including positive Phase 2b trial results for MM120 in GAD and the initiation of Phase 3 trials. Despite a net loss of $108.7 million, the company's robust pipeline and increased assets signal potential for future growth in psychedelic medicine.
March 06, 2025 MindMed Reports Promising Financial Results for 2024 MindMed Inc. has announced promising financial results for 2024, showcasing major advancements in its clinical programs for anxiety and depression. With substantial funding secured and a strong pipeline, the company is well-positioned for future growth and innovation in brain health treatments.
March 04, 2025 Mind Medicine Inc. to Showcase Innovations at Leerink’s Global Healthcare Conference Mind Medicine Inc. will showcase its innovative biopharmaceutical solutions at the Leerink’s Global Healthcare Conference on March 11, 2025. The company aims to highlight its commitment to treating brain health disorders through novel therapies and engaging discussions with investors.
February 20, 2025 Mind Medicine Inc. Set to Release 2024 Financial Results Mind Medicine Inc. will announce its financial results for Q4 and the full year 2024 on March 6, 2025. A live webcast will provide insights into the company's performance and developments, allowing stakeholders to engage with leadership and access a replay afterward.
February 08, 2025 SWOT Analysis of Mind Medicine Inc. in 2025 This SWOT analysis examines Mind Medicine Inc.'s position in 2025, highlighting its innovative product pipeline and strategic partnerships while addressing financial vulnerabilities and industry challenges. It outlines the potential for growth within the expanding market for psychedelic therapies and the risks faced in a competitive landscape.
November 07, 2024 Mind Medicine Inc. Reports Promising Developments in Q3 2024 Mind Medicine Inc. reports positive Q3 2024 results, with successful Phase 2b trial outcomes for MM120 in treating generalized anxiety disorder. The company also highlights significant financial improvements and a strong cash position, paving the way for future developments in mental health treatments.
August 13, 2024 Mind Medicine Inc. Reports Financial Results for Q2 2024: A Closer Look at Progress and Challenges Mind Medicine Inc. reported a net loss of $5.9 million in Q2 2024, significantly improved from the previous year. The company is focused on its product pipeline and securing additional funding to advance mental health treatments.
May 08, 2024 Mind Medicine Inc. Reports Substantial Losses in Q1 2024 Amid Promising Developments Mind Medicine Inc. reported significant financial losses of $54.4 million in Q1 2024, an increase from the previous year. Despite this, the company is making strides in its product pipeline, with FDA breakthrough designation for MM120 and a successful capital raise of $163.7 million, positioning it well for future growth.
